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Angiotensinogen (AGT; serpin peptidase inhibitor, clade A, member 8) is a glycoprotein that is the primary substrate 
of the renin–angiotensin–aldosterone system (RAAS) and is, 
therefore, one of the most frequently studied proteins because 
of its contributions to hypertension. Given that AGT is the pri-
mary substrate controlling the rate-limiting step of the produc-
tion of angiotensin peptides, a rise in AGT levels can lead to a 
parallel increase in the formation of the physiologically active 
enzyme angiotensin II and may ultimately result in multiple 
diseases, such as hypertension, cardiovascular disease, and 
kidney injury.1–3
The AGT gene is expressed in many human tissues, as 
determined by an analysis of cDNA sequences available on 
the Unigene website. The AGT gene is known to be highly 
expressed in the liver, heart, and brain, whereas weakly 
expressed in the adrenal gland (www.ncbi.nlm.nih.gov/
sites/entrez?db=unigene; Figure S1 in the online-only Data 
Supplement). The expression of AGT is under developmen-
tal and hormonal control in a cell type–specific manner.4 It 
is generally approved that AGT expression is predominantly 
regulated at the transcriptional level.5 Multiple cis-acting 
DNA regulatory elements and transcription factors are known 
to be important in the regulation of AGT.4,6–9 Among those 
transcription factors, CCAAT/enhancer binding protein 
(CEBP) has been shown to increase AGT promoter activity 
through binding to the promoter region6 and is important for 
the regulation of AGT in response to interleukin 6 (IL6).6,10 
The CEBP family facilitates the binding of other transcription 
factors to shared sites and contributes to efficient chromatin 
remodeling at some of these sites. This feature of CEBP func-
tion indicates that it is a pioneering factor for the assembly of 
transcription factor complexes at these sites.11
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Recent studies implicate a role for adipose AGT in blood 
pressure regulation in mice.12–14 Glucocorticoids increase 
angiotensinogen gene expression,6,15,16 whereas the effect of 
mineralocorticoids on angiotensinogen gene expression is 
unknown in any type of cell. Circulating AGT derived from 
adipose tissue is increased in obese hypertension.17–19 High 
salt intake is associated with obesity,20,21 suggesting a poten-
tial link between high salt intake and increased adipose AGT.
Although many studies have been conducted on the mecha-
nisms of AGT gene regulation, little is known about the con-
tribution of DNA methylation to regulation of the AGT gene. 
DNA methylation occurs almost exclusively at cytosines of 
CpG dinucleotides. The patterns of DNA methylation are 
faithfully replicated at every cell division once they have been 
established. DNA methylation is associated with the forma-
tion of heterochromatin and gene silencing. MECP2 (methyl-
CpG–binding protein 2) is able to directly bind to methylated 
DNA and repress methylation-based transcription.
In this study, we characterize the epigenetic regulation of 
the AGT gene. The transcriptional activity of the AGT gene 
was found to be dependent on DNA methylation. We also 
found excess circulating aldosterone and high salt intake as 
a stimulator of adipose angiotensinogen gene expression in 
humans and rats, respectively. Stimulatory signals caused 
DNA to be dynamically demethylated and led to chromatin 
relaxation in the AGT promoter.
Methods
Cell Culture
NCI H295R human adrenocortical cells (ATCC, Manassas, VA) were 
cultured in DMEM/F12 medium (Sigma Chemical Company, St 
Louis, MO) supplemented with 2% Ultroser G (Pall Biosepra, NY), 
1% ITS+Premix (BD Biosciences, Bedford, MA), and 1% penicil-
lin–streptomycin and maintained at 37°C in a humidified 5% CO2 
incubator.
Human AGT ELISA
To quantify human AGT protein in cell lysate, a human AGT 
ELISA was performed with a Human angiotensinogen ELISA kit 
(CUSABIO, Wuhan, China). Cytoplasmic extracts were isolated 
from H295R cells. Data were normalized to the total protein concen-
tration of the cytoplasmic extracts.
Real-Time Reverse Transcription Polymerase  
Chain Reaction
Quantitative real-time polymerase chain reaction (PCR) was per-
formed using the SYBR Green method. ACTB (actin, beta) and Rn18s 
(18S ribosomal RNA) were used as the reference genes for humans 
and rats, respectively. The primer sequences were as follows: human 
AGT: forward 5′-CCCTGGCTTTCAACACCTAC-3′, reverse 5′- 
GCTGTTGTCCACCCAGAACT-3′; human ACTB: forward 5′- TGGC 
ACCCAGCACAATGAA-3′, reverse 5′- CTAAGTCATAGTCCGCCT 
AGAAGCA-3′; rat Agt: forward 5′-AGCACGGACAGCACCCTATT, 
reverse 5′-AGAACTCATGGAGCCCAGTCA-3′; rat Rn18s RNA: for-
ward 5′-ACGGAAGGGCACCACCAGGA-3′, reverse 5′-CACCAC 
CACCCACGGAATCG-3′.
Bisulfite Sequencing
Genomic DNA was treated with bisulfite and amplified with prim-
ers specific for the human AGT and rat Agt promoter regions. 
The human AGT promoter regions spanning from −483 to −130 
and from −110 to +78 were amplified with the following primer 
pairs: forward 5′-GTTGAAGGTTATATATTTTATGAG-3′, 
reverse 5′-AATACCAAAAACGACACTC-3′ (−483 to −130) 
and forward 5′-GGTTTGGTTAAGTGATGTAA-3′, reverse 
5′-AAAAACAAAACCGAAAAA-3′ (−110 to +78). The rat 
Agt promoter regions spanning from −400 to −103 and from 
−57 to +236 were amplified with the following primer pairs: 
forward 5′-AATTTGATTAGATGTGTTAGAAG-3′, reverse 
5′-TTACATATTTACCCCAATTC-3′ (−400 to −103) and for-
ward 5′-TGAAGTTTATTTGTTATTAGGGTTTTT-3′, reverse 
5′-AAACTCAACTCCTACCCAATCA-3′ (−57 to +236). Eight 
cloned PCR products were chosen for analysis of CpG methylation 
status, as previously described.22–24
Chromatin Accessibility by Real-Time PCR
H295R cells were cultured in 48-well plates to 80% to 95% confluence 
before they were digested in situ with or without nuclease at 37°C 
for 1 hour, in accordance with the protocol for the EpiQ Chromatin 
Analysis Kit (BIORAD, Hercules, CA). The cells were subsequently 
lysed and genomic DNA was isolated. One hundred nanograms of 
genomic DNA was used to perform SYBR Green real-time PCR 
(qPCR) for the AGT gene and the reference gene. Each PCR was 
performed in duplicate. The qPCR data were analyzed with the data 
analysis tool of the EpiQ Chromatin Analysis Kit to determine the 
chromatin accessibility within the AGT promoter region (Figure 1). 
The human AGT promoter regions were amplified with the fol-
lowing primer pairs: forward 5′- CCCGTTTCTGGGAACCTT-3′, 
reverse 5′-AGATGCCAGAAGCGACACTC-3′ (R2; CEBP); for-
ward 5′-CAGCTATAAATAGGGCATCGTG-3′, reverse 5′- ACAA 
GACCGAGAAGGAGCTG-3′ (R1; transcription start site); for-
ward 5′- TTGCCTAAGCAAGACTCTCC-3′, reverse 5′-GGAG 
ATGTACCCCCAAGAGG-3′ (R3; CpG3); forward 5′-GAGCAG 
CTGAAGGTCACACA-3′, reverse 5′- GCAGGGGAGAGTCTTG 
CTTA-3′ (R4; CpG1,2).
Chromatin Immunoprecipitation Quantitative PCR
The chromatin immunoprecipitation (ChIP) assays were per-
formed with the LowCell# ChIP Kit (Diagenode Diagnostics, 
Liège, Belgium) in accordance with the manufacturer’s proto-
col. Anti–CEBP-β (Anti-CEBPB) polyclonal antibody (sc-150; 
Santa Cruz Biotechnology, Dallas, TX) and IgG (sc-2027; Santa 
Cruz Biotechnology) were used. Quantification of ChIP DNA was 
Figure 1. Schema of the experimental design 
for the human angiotensinogen (AGT) promoter. 
Filled lollipops denote cytosine residues. A CpG 
dinucleotide, open lollipop was not analyzed. 
Nucleotide numbers are relative to a TSS. CEBPB 
indicates CCAAT/enhancer binding protein-β; 
CHART-PCR, chromatin accessibility by real-time 
polymerase chain reaction; ChIP qPCR, chromatin 
immunoprecipitation quantitative PCR; and TSS, 
transcription start site.
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accomplished by qPCR with primers specific for the AGT pro-
moter region around the CEBPB transcription factor binding site; 
the primer sequences are the same as those used for the chromatin 
accessibility by real-time PCR assay. The results are presented as 
fold enrichment of IgG. Each sample was amplified in triplicate and 
all experiments were repeated ≥3×.
DNA Methylation Activity Assay
Using the EpiQuik DNA Methyltransferase Activity/Inhibition Assay 
Kit (Epigenetic, Farmingdale, NY), DNA methylation activity was 
quantified as the ability of nuclear extracts to methylate DNA sub-
strate. The methylated DNA was recognized with an anti–5-methyl-
cytosine antibody. Each sample was measured in triplicate.
DNA Demethylation Activity Assay
Using the EpiQuik DNA Demethylase Activity/Inhibition Assay Ultra 
Kit (Epigenetic), DNA demethylation activity was quantified as the 
ability of nuclear extracts to demethylate methylated DNA substrate. 
The methylated DNA was recognized with an anti–5-methylcytosine 
antibody. Each sample was measured in triplicate.
Statistical Analysis
Statistical significance of the differences between experimental 
groups was analyzed by using Student t test, 1-way ANOVA, or 2-way 
ANOVA. The data are expressed as mean±SEM. P values <0.05 were 
considered to be statistically significant.
Results
IL6 Treatment Results in DNA Demethylation 
Around a CEBP Binding Site and a  
Transcription Start Site
We analyzed the DNA methylation status of 17 of 18 CpG 
dinucleotides within a 525-bp fragment (−459 to +66) of the 
human AGT promoter, which contains 1 CEBP binding site 
(Figure 1). We sought to gain insight into dynamic changes 
in DNA demethylation of the AGT promoter. IL6 has been 
shown to stimulate AGT expression.25,26 IL6 treatment upregu-
lated AGT expression in a dose-dependent manner in H295R 
cells (data not shown). A preliminary comparison of DNA 
Figure 2. Dynamic changes 
in DNA methylation in the 
angiotensinogen (AGT) 
promoter. A, Changes in DNA 
methylation. Gray circles 
indicate the A allele of the G-6A 
polymorphism (rs5051). The 
−6G allele becomes a CpG 
dinucleotide, a canonical target 
site for DNA methylation. White 
circles denote unmethylated 
cytosine residues; black circles, 
methylated. B, AGT mRNA 
level. Results are given as fold 
change normalized to ACTB.  
C, AGT protein level. Interleukin 
6 (IL6) treatment increased 
angiotensinogen expression. 
Data are presented as 
mean±SEM of 3 independent 
experiments. *P<0.05, 
**P<0.005, and ***P<0.0001 vs 
–IL6 (2-way ANOVA followed 
by Bonferroni post tests). CEBP 
indicates CCAAT/enhancer 
binding protein; and TSS, 
transcription start site.
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methylation patterns of the AGT promoter was made between 
IL6 stimulation (10 ng/µL) for 24 and 72 hours in H295R 
cells. DNA demethylation around a CEBP binding site and 
a transcription start site was observed in both conditions, and 
the methylation patterns were similar with each other. We con-
cluded that the DNA demethylation required almost 24 hours 
to reach the highest levels (data not shown) and decided to 
stimulate H295R cells with IL6 (10 ng/µL) for 24 hours in 
further experiments. To determine how DNA demethylation 
and remethylation progress, we treated H295R cells with IL6 
(10 ng/µL) for 24 hours and observed the dynamic changes in 
DNA methylation patterns of the AGT promoter for 5 days. 
Nontreated cells served as a control. In cells treated with IL6, 
DNA demethylation around the CEBP binding site and the 
transcription start site was detected within 12 hours after stim-
ulation and reached a maximum level by 24 hours. CpG dinu-
cleotides around the CEBP binding site and the transcription 
start site in treated cells were remethylated to a level that was 
similar to that of nontreated cells during the next 24 hours. No 
obvious changes in CpG methylation were observed in cells of 
the control group (Figure 2A).
Gray circles indicate the A allele of the G-6A polymor-
phism (rs5051). The −6G allele becomes a CpG dinucleo-
tide, a canonical target site for DNA methylation. The results 
strongly indicated that H295R cells had −6AA genotype. 
Unmethylated or methylated cytosines were observed prob-
ably because errors happened in bisulfite sequencing or muta-
tions occurred in H295R cells.
IL6 Treatment Increases AGT Expression
AGT mRNA levels gradually increased during IL6 stimulation 
and decreased to a level that was similar to that of nontreated 
cells after stimulation. AGT mRNA levels in cells treated with 
IL6 were significantly higher than those in nontreated cells at 
12, 24, 30, and 36 hours after stimulation (Figure 2B). Similar 
changes were observed in the levels of AGT protein. At 24 
hours after stimulation, AGT protein levels in cells treated 
with IL6 were significantly higher than those in nontreated 
cells (Figure 2C).
IL6 Treatment Recruits CEBPB to the AGT 
Promoter Region
DNA hypomethylation at a CEBP binding site has been 
observed in tissues with elevated expression of AGT, and the 
site was demethylated during IL6 treatment. These observa-
tions suggest an association between CEBP and changes in 
DNA methylation. We used a ChIP assay to determine that the 
binding of CEBPB to the AGT promoter in cells treated with 
IL6 was significantly higher than that in nontreated cells. A 
steep increase in recruitment of CEBPB to the AGT promoter 
was observed during IL6 treatment. Five days after stimula-
tion, CEBPB binding in cells treated with IL6 had decreased to 
a level that was similar to levels in nontreated cells (Figure 3).
IL6 Treatment Increases Chromatin Accessibility of 
the AGT Promoter
Treatment of H295R cells with IL6 increased recruitment 
of CEBPB to its binding site in the AGT promoter. CEBPB 
has been characterized as a pioneering factor that binds to 
chromatin-embedded DNA and recruits remodeling proteins.27 
Chromatin accessibility may be important for dynamic changes 
in DNA demethylation and remethylation in a locus-specific 
manner. Chromatin accessibility by real-time PCR revealed 
that IL6 treatment significantly increased chromatin acces-
sibility around a transcription start site (R1) at 6, 12, and 24 
hours after stimulation, with accessibility increasing from 58% 
to 79% (Figure 4A). Chromatin accessibility around a CEBP 
binding site (R2) also increased, to ≈80%. At 24 hours after 
stimulation, the accessibility of treated cells was significantly 
different from that of cells in the control group (Figure 4B). 
After stimulation, the accessibility of both regions returned to 
levels that were similar to those of the control group.
In contrast, chromatin accessibility did not increase around 
the CpG3 (R3; Figure 4C) or CpG1/2 (R4) sites (Figure 4D). 
The accessibility of both regions was consistently <40%; this 
percentage indicates that the chromatin was accessible at a 
low level or was even highly inaccessible.
IL6 Treatment Reduces DNA Methylation Activity
We used a time-course analysis to determine DNA meth-
ylation and demethylation activities in nuclear extracts from 
H295R cells. IL6 treatment significantly reduced DNA meth-
ylation activity at 12, 24, 30, 36, and 48 hours after stimulation 
(Figure 5A). No obvious differences in DNA demethylation 
activity were observed between IL6-treated cells and those of 
the control group (Figure 5B). These results suggest a poten-
tial role for decreased DNA methylation activity during the 
process of DNA demethylation and remethylation.
Discussion
In contrast with readily reversible histone modifications, 
DNA methylation was generally accepted to be a relatively 
static epigenetic modification. Recent findings, however, sup-
port the emerging concept that DNA methylation patterns 
are not always stable.28–30 DNA methylation is a well-known 
mechanism for gene silencing, but comparatively little is 
known about where changes in DNA methylation occur and 
how DNA methylation is rapidly reversed in a locus-specific 
Figure 3. Interleukin 6 (IL6)–induced CCAAT/enhancer binding 
protein-β (CEBPB) recruitment to the angiotensinogen (AGT) 
promoter. Data are shown as fold enrichment relative to IgG of 
3 independent experiments (mean±SEM). *P<0.05, **P<0.005, 
and ***P<0.0001 vs –IL6 (2-way ANOVA followed by Bonferroni 
post tests).
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manner. Our study revealed that the stimulatory signals of 
IL6, excess circulating aldosterone, and high salt intake all 
led to DNA demethylation around a CEBP binding site and a 
transcription start site, where chromatin structure was relaxed. 
DNA demethylation was detected within 12 hours after IL6 
treatment, whereas the highest level of demethylation was evi-
dent by 24 hours.
Irrespective of the type of stimuli, DNA demethylation 
around a CEBP binding site and a transcription start site in the 
angiotensinogen gene promoter was accompanied by increased 
angiotensinogen gene expression in both humans and rats. The 
CEBP family of proteins has been reported to pioneer chroma-
tin remodeling and maintain chromatin accessibility.11 Taken 
together, our findings indicate that CEBP family members 
initiate chromatin relaxation and transcription, which are fol-
lowed by DNA demethylation around a CEBP binding site and 
a transcription start site in the angiotensinogen gene promoter.
The molecular regulatory effects of IL6 on AGT expres-
sion have been extensively investigated in human liver cells. 
In addition to CEBP family members, NR3C1, STAT3, and 
HNF1A that bind to the nucleotide sequence located between 
−162 and −278 of the AGT promoter are involved in IL6-
induced activation of AGT (Figure S4A).31 Because the AGT 
promoter was fully unmethylated in human liver HepG2 cells, 
we were unable to use these cells to analyze changes in DNA 
methylation (Figure S2). Instead, we used human adrenocor-
tical H295R cells that had a partially methylated AGT pro-
moter (Figure 2A). In H295R cells, IL6 treatment upregulated 
AGT expression in a similar manner with HepG2 cells and 
was accompanied by extensive demethylation from CpG5 
(−281/−282) to CpG11 (−152/−153; Figure 2A). These results 
suggest that transcription factors CEBP, NR3C1, STAT3, and 
HNF1A may be involved in the upregulation of AGT and DNA 
demethylation of this gene promoter in H295R cells as is the 
case with human liver cells.
We have shown for the first time that circulating aldosterone 
in patients with aldosterone-producing adenoma (APA) leads 
to increased AGT expression in visceral adipose tissue (Figure 
S5C). Aldosterone is ≈1000× less than cortisol in the circu-
lating blood (Table S1). Aldosterone and cortisol, although 
both corticosteroids, regulate AGT differently: aldosterone is 
a more potent activator of AGT expression than is cortisol. 
RAAS is a system of major importance in the control of fluid 
and electrolyte homeostasis. Thus, aldosterone seems to exert 
a physiologically relevant effect on AGT expression. This pos-
itive feedback effect may be an innate capacity to efficiently 
retain fluid in land dwelling mammalian species. Excessive 
salt in contemporary diets depresses the circulating RAAS.32 
DNA hypermethylation of the AGT promoter in adipose tis-
sue from NFA (non-functioning adrenocortical adenoma) may 
reflect depressed levels of the circulating RAAS in contempo-
rary humans.
Two receptor systems, the glucocorticoid receptor system 
(NR3C1) and the mineralocorticoid receptor system (NR3C2), 
differentially modulate corticosteroid actions in adipose tis-
sue.33 Glucocorticoid receptor and mineralocorticoid receptor 
bind to a common corticosteroid response element. The CEBP 
binding site (−217 to −225) is also known to interact with cor-
ticosteroid receptors.6 CEBPB and glucocorticoid receptor 
have been reported to cooperatively and specifically regulate 
Figure 4. Changes in chromatin accessibility within the angiotensinogen (AGT) promoter. A, Transcription start site (TSS). B, CCAAT/
enhancer binding protein (CEBP) binding site. C, CpG2 and 3 sites. D, CpG1 site. Data are presented as mean±SEM of 3 independent 
experiments. *P<0.05, **P<0.005 vs – interleukin 6 (IL6; 2-way ANOVA followed by Bonferroni post tests).
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chromatin accessibility and remodeling at co-occupied sites.11 
A CpG dinucleotide at the CEBP binding site (−217 to −225) 
was hypomethylated in adipose tissue of patients with APA, 
whereas this site was hypermethylated in the tissue of patients 
with Cushing syndrome (CS; Figure S5A and S5B). The dif-
ference in DNA methylation at the CEBP binding site between 
patients with APA and those with CS suggests differential 
actions of corticosteroids in human adipose tissue via interac-
tions between corticosteroid receptors and CEBP.
Glucocorticoids are well-known activators of angioten-
sinogen gene expression in humans and rodents.6,15,16 Three 
putative corticosteroid response elements (gtccct, −371 
to −376; ctctg, −393 to −397; ctctg, −400 to −404) exist in 
the vicinity of CpG2 and CpG3 (Figure S4A). DNA hypo-
methylation at CpG2/3 sites and around a transcription start 
site was observed in visceral adipose tissue of patients with 
CS. Cortisol-induced recruitment of corticosteroid receptors 
might cause DNA demethylation at these 2 CpG sites and 
activate AGT transcription in cases of CS. Hypertension is a 
prominent characteristic of APA and CS. Although elevation 
in arterial pressure is primarily induced by aldosterone and 
cortisol in APA and CS, respectively, increased AGT expres-
sion from visceral adipose tissue may contribute, in part, to 
the development of hypertension in both conditions.
High salt intake suppresses the circulating RAAS. Salt 
intake can affect sympathetic nerve activity and lead to 
changes in the gene expression profile of adipose tissue. Agt 
expression was paradoxically increased in visceral adipose 
tissue from Wistar-Kyoto rats fed a high-salt diet (Figure 
S6D). This result suggests that salt-dependent hypertension 
in humans may be, in part, dependent on increased AGT 
expression in visceral adipose tissue. More importantly, 
DNA hypomethylation at CEBP binding sites and a tran-
scription start site coincided with increased Agt expression 
in rat visceral adipose tissue (Figure S6A–S6D). This finding 
indicates that a close association exists between DNA hypo-
methylation at CEBP binding sites and increased angioten-
sinogen gene expression in both humans and rats.
Figure 6. Conversion of the gene expression 
phenotype. Stimulatory signals switch the gene 
expression phenotype within a tissue from an 
inactive to an active state. After stimulation, the 
gene expression phenotype gradually restores to 
its former state. AGT indicates angiotensinogen; 
CEBP, CCAAT/enhancer binding protein; and TSS, 
transcription start site.
Figure 5. Changes in DNA methylation and demethylation 
activities. A, DNA methylation activity. B, DNA demethylation 
activity. *P<0.05, **P<0.005, and ***P<0.0001 vs – interleukin 6 
(IL6; 2-way ANOVA followed by Bonferroni post tests).
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We have shown that DNA methylation at CpG dinucleo-
tides alters gene expression by affecting transcription factor 
binding activity.23 However, the effects of CpG methylation 
on binding activities of transcription factors with the AGT 
promoter were limited (Figure S4B and S4C). CpG methyla-
tion increased MECP2 binding activities with the AGT pro-
moter (Figure S4D). These observations suggest that MECP2 
recruitment to methylated CpG dinucleotides would play 
a crucial role in transcriptional repression of AGT by DNA 
methylation.
Functional DNA demethylation is accompanied by chro-
matin accessibility.34 Subtle change in topology of nucleoso-
mal DNA in promoter regions can play an important role in 
gene regulation.35 After IL6 stimulation, we detected an open 
chromatin structure only around a transcription factor binding 
site and a transcription start site. Thus, chromatin accessibility 
plays a crucial role in gene regulation.
DNA methylation is established and maintained by DNA 
methyltransferases. DNA methyltransferase 3A and 3B 
are responsible for de novo DNA methylation, whereas 
DNA methyltransferase 1 maintains DNA methylation pat-
terns through successive rounds of cell division.36 DNA 
demethylation can occur through an active or passive path-
way. Active DNA demethylation is the postulated process 
whereby 5-methylcytosine is sequentially modified, excised, 
and replaced by the DNA repair machinery. By contrast, 
passive DNA demethylation refers to the loss of the methyl 
radical from 5-methylcytosine when DNA methyltransferase 
1 is inhibited or absent during successive rounds of DNA 
replication.37 In our study, DNA demethylation of the AGT 
promoter was associated with decreased DNA methylation 
activities (Figure 5A; Figure S6E). This association suggests 
that passive, rather than active, DNA demethylation may be 
a more likely cause. The balance between DNA methylation 
and demethylation activities may be a major determinant for 
DNA methylation status.
Perspectives
Stimulatory signals can orchestrate locally transcription fac-
tor recruitment, open chromatin configuration, and DNA 
demethylation in a locus-specific manner and globally a 
reduction in DNA methylation activity in the nucleus. Any 
type of continuous signal could elicit changes in DNA meth-
ylation to globally control the balance between DNA meth-
ylation and demethylation activities. DNA methylation status 
can be used to trace the amount of chromatin that is opened 
by transcription factors at specific sites and functions as a 
memory to maintain responsiveness of gene expression to 
additional signals. DNA demethylation converts the gene 
expression phenotype within a tissue from an inactive to an 
active state (Figure 6).
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What Is New?
•	We demonstrate dynamic changes of DNA methylation as to where 
changes in DNA methylation occur and how rapidly DNA demethylation 
and remethylation progress in the angiotensinogen gene (AGT) promoter.
•	Excess circulating aldosterone and high salt intake upregulate adipose 
AGT expression in humans and rats, respectively.
What Is Relevant?
•	 Increased AGT expression from visceral adipose tissue may contribute 
to the development of hypertension in APA (aldosterone-producing ad-
enoma) and CS.
•	Salt-dependent hypertension may depend on increased AGT expression 
in visceral adipose tissue.
Summary
DNA methylation negatively regulates the AGT expression and dy-
namically changes in response to continuous stimulation in the 
AGT promoter. The methylation patterns function as a memory to 
maintain responsiveness of gene expression to additional signals. 
Stimulatory signals convert the gene expression phenotype within 
a tissue from an inactive to an active state.
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Materials and Methods 
Tissue distribution of the AGT gene expression 
We determined the expression profile of the AGT gene by the analysis of expressed sequence 
tag counts publicly available at the UniGene web site (Supplementary Fig. S1). 
 
AGT promoter constructs 
Luciferase reporter plasmids containing various fragments of the 5’-flanking region of the 
AGT promoter were prepared from human genomic DNA using PCR (Figure S3A). After 
digestion with KpnI and NheI, the reporter constructs were synthesized by PCR amplification 
of human AGT gene using TTTGCACAGGGTAGGCTCTT, 
TGTGTAACTCGACCCTGCAC and TGGTCTGGCCAAGTGATGTA as the respective 
forward primers and CCGGCTTACCTTCTGCTGTA as the reverse primer. The amplified 
fragments contained the nucleotide sequence -511 to +44, -238 to +44 and -112 to +44, 
respectively. The forward primer had the KpnI restriction site and the reverse primer had the 
NheI restriction site so that amplified fragments could be subcloned in the pGL4.10 basic 
vector. Inserts were sequenced to ensure fidelity of the amplified sequences. 
 
Luciferase assay 
SssI methylase (New England Biolabs Japan Inc., Tokyo, Japan) was used for in vitro 
methylation of AGT promoter luciferase constructs in the pGL4.10 vector. In each case, half 
of the DNA sample was methylated using SssI and the other half was incubated with SssI 
methylase in the absence of S-adenosylmethionine (mock-methylation). The efficiency of 
methylation or mock-methylation was determined through digesting modified constructs with 
restriction endonuclease BsiEi (New England Biolabs Japan Inc., Tokyo, Japan). 
Adrenocortical H295R cells were transfected using FuGene HD (Roche Laboratories, Basel, 
Switzerland) with the following plasmids: (1) 100 ng of modified pGL4.10 firefly luciferase 
reporter plasmid containing methylated or unmethylated AGT promoter and (2) 10 ng of 
pRL-TK Renilla luciferase control reporter vector that contains a cDNA encoding Renilla 
luciferase (Promega, Madison, WI, USA) as an internal control for transfection efficiency. 
The day before transfection, H295R cells were seeded onto a 96-well plate and transfected at 
80% confluency. Cells were incubated for 48h following transfection. Firefly and Renilla 
luciferase assays were performed using 10ul of cell lysates and a dual-luciferase reporter 
assay system kit (Promega). Results are reported as the average of triplicate assays and are 
expressed as a ratio to the internal standard Renilla luciferase. 
 
Enzyme-linked immunosorbent assay-based electrophoretic mobility shift assay 
(NoShift assay)  
Nuclear extracts were isolated from H295R cells and HepG2 cells according to the 
manufacturer’s protocol with the NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Fisher Scientific, Yokohama, Japan). Protein concentration was determined using a 
BCA protein assay (Thermo Fisher Scientific) with BSA as a standard. The enzyme-linked 
immunosorbent assay-based electrophoretic mobility shift assay was carried out using 
NoShift transcription factor assay kits (TAKARA BIO INC., Otsu, Japan) according to the 
manufacturer’s protocol. 6 µg of nuclear extracts was incubated on ice for 30 min with each 
of the biotinylated oligonucleotides including J region (HNF4A/NR2F1 binding site), 
CEBPB/NR3C1 binding site with -217A or G allele and USF1/ESR1 binding site with -20A 
or C allele in the presence or absence of CpG dinucleotides methylation (10 pmole), together 
with 500 ng salmon sperm DNA and 0.01U Poly (dI-dC) in 1ൈ NoShift binding buffer. After 
1 hour of incubation at 37ºC on streptavidin-coated microassay plates, samples were 
incubated with anti-USF1 (sc-229; Santa Cruz Biotechnology), anti-ESR1 (sc-544; Santa 
Cruz Biotechnology), anti-CEBPB (sc-150; Santa Cruz Biotechnology), anti-NR3C1 
(sc-8992; Santa Cruz Biotechnology), anti-HNF4A (sc-8987; Santa Cruz Biotechnology), 
anti-NR2F1 (sc-28611; Santa Cruz Biotechnology) and anti-MECP2 (pAb-052-050; 
Diagenode s.a., Lige, Belgium) antibodies respectively and further incubated at 37ºC for 1 
hour. Bound transcription factor was then detected using a specific secondary horseradish 
peroxidise conjugate antibody. After intensive washing to remove the secondary antibody, 
TMB substrate and 1N HCL (stop solution) were added before the plates were read at 450nm 
wavelength. Sequences of the biotinylated double-stranded oligonucleotides are listed as 
follows: Unmethylated probe with -20A: 5’-AGGGCATCGTGACCCG-biotin-3’, 
Methylated probe with -20A: 5’-AGGGCATCmGTGACCCG-biotin-3’, Unmethylated probe 
with -20C: 5’-AGGGCCTCGTGACCCG-biotin-3’, Methylated probe with -20C: 
5’-AGGGCCTCmGTGACCCG-biotin-3’, Unmethylated probe with -217G: 
5’-TCGACCCTGCACCGGCTCACTCTGTTCAGCAGT-biotin-3’, Methylated probe with 
-217G: 5’-TCGACCCTGCACCmGGCTCACTCTGTTCAGCAGT-biotin-3’, Unmethylated 
probe with -217A: 5’-TCGACCCTGCACCAGCTCACTCTGTTCAGCAGT-biotin-3’, 
Unmethylated probe within J region: 5’-TCTGGGAACCTTGGCCCCGACTC-biotin-3’, 
Methylated probe within J region: 5’-TCTGGGAACCTTGGCCCCmGACTC-biotin-3’. 
 
Procurement of human tissue 
Visceral adipose tissue surrounding the adrenal gland was obtained from 27 patients 
including 10 patients with aldosterone-producing adenoma (APA), 7 patients with Cushing 
syndrome (CS), and 10 patients with non-functioning adrenocortical adenoma (NFA) 
(Supplementary Table S1). Human tissue samples were obtained from Kanazawa University 
Hospital (Kanazawa, Japan), Tohoku University Hospital (Sendai, Japan), and Ishikawa 
Central Prefectural Hospital (Kanazawa, Japan). All samples were frozen in liquid nitrogen 
and stored at -80°C. All experimental protocols were approved by the Institutional Review 
Boards of Kanazawa University, Tohoku University, and Ishikawa Central Prefectural 
Hospital. The purpose of the study was explained to all patients, and written informed 
consent was obtained from each study participant.  
 
Animal experiments 
Visceral adipose tissue was obtained from Wistar Kyoto (WKY) rats that were fed either 
low-sodium (0.45%) or high-sodium (7%) chow for 8 weeks (n= 5, each group). All 
experiments were performed in accordance with the guidelines for the use of experimental 
animals of the Animal Research Committee of Kanazawa University. 
  
Results 
DNA methylation within a CEBP binding site appears to be inversely associated with 
AGT expression in human tissues 
AGT expression is high in the liver, heart, and brain, compared to the adrenal gland 
(Supplementary Fig. S1). Bisulfite sequencing showed that a CpG dinucleotide within the 
CEBP binding site was hypomethylated in tissues from the liver and heart, whereas 
hypermethylated in those from the adrenal gland and leukocytes (Supplementary Fig. S2). 
CpG dinucleotides within the AGT promoter region were completely unmethylated in the 
human liver cell line, HepG2. Thus, methylation status of a CpG dinucleotide within the 
CEBP binding site appeared to be inversely associated with AGT expression. 
 
DNA methylation strongly represses the AGT promoter activity  
To assess the effect of DNA methylation on the AGT transcriptional activity, we synthesized 
luciferase reporter constructs containing varying lengths of the AGT promoter either with or 
without CpG methylation (Supplementary Fig. S3A). We used constructs with AA at -6 
(rs5051), AA at -20 (rs5050) and GG at -217 (rs5049). DNA methylation abolished the AGT 
promoter transcription activities (Supplementary Fig. S3B), indicating the AGT promoter was 
dependent on DNA methylation. 
 
DNA methylation affects DNA-protein interaction in vitro 
Several polymorphisms in the 5’-flanking region of the human AGT gene including the -20 
and -217 polymorphisms affect the AGT regulation 1. Allele-specific transcription factors 
such as USF1 preferential binding to -20C and ESR1 binding to -20A are associated with 
increased AGT promoter activity2. Previous genetic study also indicated that HNF4 may 
strongly activate the AGT transcription through binding J region (HNF4A/NR2F1 binding 
site) within the AGT promoter, but NR2F1, a transcriptional repressor, dramatically represses 
the human AGT transcription 3. These transcription factors bind to important elements 
containing CpG dinucleotides which are target sites for DNA methylation (Supplementary 
Fig. S4A). There is now abundant evidence that DNA methylation affects DNA-protein 
interactions and may have a function in all processes in which such interactions occur. We 
performed in vitro analysis to determine the functional significance of methylation in the 
AGT promoter region by analysing the binding potential of methylated or unmethylated 
oligonucleotides (analogous to putative AGT regulatory elements) to nuclear proteins from 
H295R and HepG2. NoShift assay showed DNA methylation impaired USF1 binding at -20 
with A or C in both cell lines. However, DNA methylation had little effects on activators 
ESR1, CEBPB, NR3C1 and HNF4A binding to the corresponding elements (Supplementary 
Figs. S4B and C). DNA methylation increased NR2F1 binding in HepG2 cells 
(Supplementary Fig. S4C) and MECP2 binding in both cell lines (Supplementary Fig. S4D). 
 
Excess circulating aldosterone induces DNA demethylation of the AGT promoter and 
increases mRNA levels in human adipose tissue 
We simultaneously determined the DNA methylation status and mRNA levels of the AGT 
gene in visceral adipose tissue from patients with APA, CS, and NFA. The AGT promoter, 
including 1 CEBP binding site, was largely unmethylated in patients with APA 
(Supplementary Fig. S5A and B); this finding contrasts with those in patients with CS and 
NFA. AGT mRNA levels in adipose tissue were consistently higher in patients with APA 
than in patients with NFA (Supplementary Fig. S5C). These results demonstrate that excess 
circulating aldosterone leads to demethylation of the AGT promoter, including the CEBP 
binding site and the transcription start site, and activation of the AGT gene in human adipose 
tissue. 
DNA at CpG2/3 and DNA around a transcription start site (CpG12 to 15) were both 
hypomethylated in adipose tissue of patients with CS, and the levels of methylation were 
comparable to that in the tissue of patients with APA (Supplementary Fig. S5A and B). 
Although the difference was not statistically significant, AGT mRNA levels in adipose tissue 
tended to be higher in patients with CS than in patients with NFA (Supplementary Fig. S5C). 
Although to a lesser extent than with aldosterone, excess circulating cortisol also leads to 
demethylation and upregulation of AGT. 
 
High salt intake induces DNA demethylation of the Agt promoter and increases mRNA 
levels in rat adipose tissue 
We analyzed the DNA methylation status of 12 out of 13 CpG dinucleotides within a 571 bp 
fragment (-364 to +207) of the rat Agt promoter, which contains 2 CEBP binding sites 
(cttgctcca, +2 to +10; ctgggaa, +78 to +84; Supplementary Fig. S6A). We simultaneously 
determined both DNA methylation status and mRNA levels of the Agt gene in visceral 
adipose tissue from Wistar-Kyoto rats fed either a high- or low-salt diet. CpG dinucleotides 
around the CEBP binding sites and a transcription start site were hypomethylated in rats fed a 
high-salt diet (Supplementary Fig. S6B and C). Levels of Agt mRNA were consistently 
higher in rats fed a high-salt diet than in those fed a low-salt diet (Supplementary Fig. S6D). 
These results demonstrate that high salt intake leads to demethylation of CEBP binding sites 
and a transcription start site of the Agt promoter and activation of the Agt gene in rat visceral 
adipose tissue, as was observed at the AGT promoter of human visceral adipose tissue. 
DNA methylation activity in nuclear extracts was significantly lower in rats fed a high-salt 
diet than in those fed a low-salt diet (Supplementary Fig. S6E). No significant differences in 
DNA demethylation activity were observed between rats fed either a high- or low-salt diet 
(Supplementary Fig. S6F). A high salt intake-induced decrease in DNA methylation activity 
may play a crucial role in DNA demethylation of the Agt promoter. 
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Supplementary Table S1. Characteristics of patients with adrenocortical adenoma 
Variables APA CS NFA 
Age, yr 53.4±10.2 52.0±19.1 55.0±9.43 
Systolic blood pressure, mmHg 134.3±10.9 147.0±20.7 129.1±25.1 
Diastolic blood pressure, mmHg 79.3±16.8 91.6±13.9 75.4±15.2 
















Data are shown as mean±S.D. APA indicates aldosterone-producing adenoma; CS, Cushing 
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performed using antibodies against USF1, ESR1, CEBPB (C/EBPβ), NR3C1 (GR), HNF4A, 
NR2F1 and MECP2 in both H295R and HepG2 cells. Percent change in transcription factors 
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entary Figure S6 
High salt intake-induced DNA demethylation with increased Agt expression in rat 
visceral adipose tissue. A, CpG dinucleotides within the rat Agt promoter. Filled lollipops 
denote cytosine residues. A CpG dinucleotide, white lollipop was not analysed. TSS, 
transcription start site. Nucleotide numbers are relative to a TSS. B, DNA methylation status 
of the Agt promoter. C, DNA methylation ratios. Data are presented as mean±SEM. *P <0.05, 
**P < 0.005 and ***P < 0.0001 vs LS (2-way ANOVA followed by Bonferroni posttests). D, 
Agt mRNA level. Results are given as fold change normalized to Rn18s. E, DNA methylation 
activity. F, DNA demethylation activity. WKY, Wistar-Kyoto rats; HS, high salt diet; LS, low 
salt diet. Data are presented as mean±SEM. **P < 0.005, ***P < 0.0001 (2-tailed unpaired t 
test). 
 
 
 
 
 
